Indoco Remedies Ltd, a Rs.475 crore plus pharm giant, has decided to issue bonus share and sub divide its share of Rs.10 each. A meeting of the Board of Directors of the company will be held on March 29, 2012 to consider bonus share ratio and sub division. Indoco scrip moved up sharply by Rs.21 to Rs.405 on BSE.
Indoco has a strong brand portfolio of 120 products in various therapeutic segments, including high growth life style segments such as anti-infectives, anti-diabetics, cardiovascular, ophthalmology, dental care, pain management and respiratory. Top Indoco brands include Cyclopam, Vepan, Febrex Plus, ATM, Sensodent–K, and Sensoform. Indoco has nine manufacturing facilities for Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in India.
Indoco also has a state-of-the-art research centre at Navi Mumbai with over 200 scientists. With approval of its Finished Dosage facilities by the US-FDA, Darmstadt-Germany, TGA Australia, MCC-South Africa and UK-MHRA, Indoco Remedies has emerged as the most suitable partner and provider of Contract Research and Manufacturing Services (CRAMS) to its customers globally.
Recently, Indoco Remedies has entered marketing agreement with Royal DSM N.V., for eight Active Pharmaceutical Ingredients (APIs) and the alliance came into effect in January 2012. This marketing tie- up will leverage Indoco's product development and cGMP (current Good Manufacturing Practices) compliant manufacturing capabilities and DSM's market access.